Ecnoglutide
vs Mazdutide.
Compare ecnoglutide and mazdutide by China approvals, GLP-1 versus GLP-1/glucagon mechanisms, Phase 3 results, doses, safety, and worldwide status.
What is the difference?
Ecnoglutide and mazdutide are different once-weekly peptide medicines with indication-specific approvals in China and no head-to-head trial against each other. Ecnoglutide is a cAMP-biased GLP-1 receptor agonist approved in China for type 2 diabetes and chronic weight management in 2026. Mazdutide activates GLP-1 and glucagon receptors and received Chinese approvals for chronic weight management and type 2 diabetes in 2025. Neither is FDA approved. Their pivotal weight percentages came from separate Chinese Phase 3 programs, so the results cannot establish that one approved product is more effective, safer, or more available than the other.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
Ecnoglutide
Approved in China for type 2 diabetes and chronic weight management; not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 15 matched NCT records
- Sponsor
- Sciwind Biosciences; Pfizer commercialization partner in Mainland China
Mazdutide
Approved in China for chronic weight management and type 2 diabetes; not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 37 matched NCT records
- Sponsor
- Innovent Biologics; licensed from Eli Lilly for China
Ecnoglutide vs Mazdutide: how direct is the evidence?
No participant in the cited sources was randomized between Ecnoglutide and Mazdutide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
Ecnoglutide
cAMP-signalling-biased GLP-1 receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- China approvals active; indication-expansion studies continue
- Status
- Approved in China for type 2 diabetes and chronic weight management; not FDA approved
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialMazdutide
GLP-1 and glucagon receptor dual agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- China approvals active; Phase 3 and indication-expansion studies continue
- Status
- Approved in China for chronic weight management and type 2 diabetes; not FDA approved
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 3
- Results posted
- 0
- Recruiting site observations
- 3
matched NCT records
- Recruiting
- 10
- Results posted
- 1
- Recruiting site observations
- 73
Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
Ecnoglutide
cAMP-signalling-biased GLP-1 receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- China approvals active; indication-expansion studies continue
- Status
- Approved in China for type 2 diabetes and chronic weight management; not FDA approved
- Featured trial anchors
- NCT05813795 · NCT05680155 · NCT05680129
Mazdutide
GLP-1 and glucagon receptor dual agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- China approvals active; Phase 3 and indication-expansion studies continue
- Status
- Approved in China for chronic weight management and type 2 diabetes; not FDA approved
- Featured trial anchors
- NCT05607680 · NCT06164873 · NCT06184568 · NCT05606913
Compare the field, then read the limit.
This pair is valuable because both names now represent real China-specific medicine approvals while also appearing in global pipeline records and online vial listings. A defensible comparison keeps the distinct mechanisms, approved indications, product records, doses, trial populations, estimands, adverse-event reports, and commercialization arrangements attached. It also prevents a Chinese approval from being misread as worldwide authorization or proof that a seller outside China offers an approved product.
| Field | Ecnoglutide | Mazdutide | How to interpret it |
|---|---|---|---|
| Mechanism | cAMP-biased GLP-1 receptor agonist | GLP-1 and glucagon receptor dual agonist | The receptor strategies differ, and mechanism alone cannot establish comparative efficacy, safety, or product suitability. |
| China approvals | Type 2 diabetes in January 2026; chronic weight management in March 2026 | Chronic weight management in June 2025; type 2 diabetes in September 2025 | Both have real Chinese approvals, but each indication, presentation, authorization holder, and current supply record remains product-specific. |
| Weight evidence anchor | 15.4% at 48 weeks with 2.4 mg in SLIMMER under a treatment-policy estimand | 14.01% at 48 weeks with 6 mg in GLORY-1; 16.65% at 60 weeks with 9 mg in GLORY-2 | Separate programs, doses, durations, and analysis plans prevent a winner claim despite similar-looking percentages. |
| US status | Not FDA approved | Not FDA approved | NMPA approvals do not create an FDA application, US label, pharmacy product, insurance policy, or lawful seller route. |
| Online identity boundary | Approved Sciwind product records must match exactly | Approved Innovent product records must match exactly | A research vial or marketplace listing cannot inherit approval by using the ingredient name, local currency, or a China-shipping claim. |
Why the headline numbers do not name a winner.
Sciwind reported 15.4% mean change with ecnoglutide 2.4 mg at week 48 under the treatment-policy estimand in SLIMMER, with a 15.1% placebo-adjusted difference. Mazdutide GLORY-1 reported 14.01% mean change with 6 mg at week 48 versus a 0.30% gain with placebo, while GLORY-2 later studied 9 mg for 60 weeks. These were not randomized against each other. Dose, population, endpoint timing, analysis, placebo response, and approved presentation all differ, so a numerical subtraction is not comparative effectiveness evidence.
Keep the comparison honest.
- 01
Attach every China approval to its exact indication, authorization holder, presentation, approval date, and current national product record.
- 02
Do not rank SLIMMER, GLORY-1, and GLORY-2 percentages as though they came from one randomized protocol with matching doses and estimands.
- 03
Keep China approval separate from FDA approval, authorization elsewhere, seller licensing, import status, product identity, and current local supply.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →